Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the findings from a Phase II trial (NCT03586609) investigating cladribine (CLAD) with low-dose cytarabine (LDAC) and venetoclax (Ven), alternated with azacytidine and Ven, for acute myeloid leukemia (AML). Patients responded well to this treatment regimen, with favorable overall survival (OS), even in patients with higher-risk RAS mutations. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.